ReviewCNS & neurological disorders drug targets2015
The Actin Cytoskeleton as a Therapeutic Target for the Prevention of Relapse to Methamphetamine Use.
Review in CNS & neurological disorders drug targets, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Neurostructural alterations, trait impulsivity, and genetic architecture in individuals with methamphetamine dependence: a multimodal imaging-genetics study.Translational psychiatry · 2026Article
- Article
- The Proteomic Landscape of Parkin-Deficient and Parkin-Overexpressing Rat Nucleus Accumbens: An Insight into the Role of Parkin in Methamphetamine Use Disorder.Biomolecules · 2025Article
- METH exposure alters sperm DNA methylation in F0 mice and mPFC transcriptome in male F1 mice.Psychopharmacology · 2024Article
- Article
- Targeting the cytoskeleton as a therapeutic approach to substance use disorders.Pharmacological research · 2024Review
- Modeling methamphetamine use disorder and relapse in animals: short- and long-term epigenetic, transcriptional., and biochemical consequences in the rat brain.Neuroscience and biobehavioral reviews · 2023Review
- Preliminary PET Imaging of Microtubule-Based PET Radioligand [ACS chemical neuroscience · 2023Article
- Neuropsychiatric Model of Addiction Simplified.The Psychiatric clinics of North America · 2022Review
- Circadian transcription factor NPAS2 and the NADThe European journal of neuroscience · 2022Article
- Control of actin polymerizationFrontiers in cell and developmental biology · 2022Review
- Neuromechanobiology: An Expanding Field Driven by the Force of Greater Focus.Advanced healthcare materials · 2021Review
- Parkin regulates drug-taking behavior in rat model of methamphetamine use disorder.Translational psychiatry · 2021Article
- Effects of berberine hydrochloride on methamphetamine-induced anxiety behaviors and relapse in rats.Iranian journal of basic medical sciences · 2020Article
- PET Imaging of [Molecules (Basel, Switzerland) · 2020Article
- Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.Natural product reports · 2020Review
- Methamphetamine Learning Induces Persistent and Selective Nonmuscle Myosin II-Dependent Spine Motility in the Basolateral Amygdala.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020Article
- Methamphetamine-associated cognitive decline is attenuated by neutralizing IL-1 signaling.Brain, behavior, and immunity · 2019Article
- The role of nonmuscle myosin II in polydrug memories and memory reconsolidation.Learning & memory (Cold Spring Harbor, N.Y.) · 2018Article
- Memory disrupting effects of nonmuscle myosin II inhibition depend on the class of abused drug and brain region.Learning & memory (Cold Spring Harbor, N.Y.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A high rate of relapse is a defining characteristic of substance use disorder for which few treatments are available. Exposure to environmental cues associated with previous drug use can elicit relapse by causing the involuntary retrieval of deeply engrained associative memories that trigger a strong motivation to seek out drugs. Our lab is focused on identifying and disrupting mechanisms that support these powerful consolidated memories, with the goal of developing therapeutics. A particularly promising mechanism is regulation of synaptic dynamics by actin polymerization within dendritic spines. Emerging evidence indicates that memory is supported by structural and functional plasticity dendritic spines, for which actin polymerization is critical, and that prior drug use increases both spine and actin dynamics. Indeed we have found that inhibiting amygdala (AMY) actin polymerization immediately or twenty-four hours prior to testing disrupted methamphetamine (METH)-associated memories, but not food reward or fear memories. Furthermore, METH training increased AMY spine density which was reversed by actin depolymerization treatment. Actin dynamics were also shifted to a more dynamic state by METH training. While promising, actin polymerization inhibitors are not a viable therapeutic, as a multitude of peripheral process (e.g. cardiac function) rely on dynamic actin. For this reason, we have shifted our focus upstream of actin polymerization to nonmuscle myosin II. We and others have demonstrated that myosin IIb imparts a mechanical force that triggers spine actin polymerization in response to synaptic stimulation. Similar to an actin depolymerizing compound, pre-test inhibition of myosin II ATPase activity in the AMY produced a rapid and lasting disruption of drug-seeking behavior. While many questions remain, these findings indicate that myosin II represents a potential therapeutic avenue to target the actin cytoskeleton and disrupt the powerful, extinction-resistant memories capable of triggering relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.